Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01 - Clinical Trial Not Allowed)
ID: 353483Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353483

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-198.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01 - Clinical Trial Not Allowed)." This initiative aims to explore the cellular and molecular mechanisms that affect the blood-brain barrier during passive anti-beta-amyloid immunotherapy, particularly in the context of Alzheimer's disease and related dementias. The program is significant for advancing the understanding of ARIA, which is crucial for improving the safety and efficacy of Alzheimer's therapeutics. Eligible applicants include various academic institutions, nonprofits, and state and local governments, with a funding ceiling of $500,000 per project per year, totaling up to $3.75 million annually for up to five projects. Interested parties must submit their applications by November 5, 2024, and can direct inquiries to grantsinfo@nih.gov or visit the opportunity's webpage for more details at https://grants.nih.gov/grants/guide/pa-files/PAR-24-198.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-198-Full-Announcement.html
    PAR-24-198.html
    The Department of Health and Human Services has issued a funding opportunity aimed at exploring protective strategies to mitigate Amyloid-Related Imaging Abnormalities (ARIA) resulting from passive anti-beta-amyloid immunotherapy. This initiative, managed by the National Institutes of Health, specifically the National Institutes of Neurological Disorders and Stroke and the National Institute on Aging, seeks to uncover the cellular and molecular mechanisms impacting the blood-brain barrier during treatment for Alzheimer's disease and related dementias. Applications are welcomed for studies that leverage animal models to investigate the negative effects of this immunotherapy, particularly in relation to risk factors like age and APOE4 carrier status. Funding totals up to $3.75 million annually for up to five awarded projects, with each project limited to direct costs of $500,000 per year. Eligibility is extended to various academic institutions, nonprofits, and state and local governments, although foreign organizations are excluded. The submission process requires adherence to strict application guidelines and will not accept projects involving clinical trials. By fostering a better understanding of ARIA, the initiative aims to enhance the efficacy and safety of Alzheimer's therapeutics while addressing significant barriers in the field of Alzheimer's research.
    Similar Opportunities
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Alzheimer's Drug-Development Program (Funding Opportunity Number: PAR-24-223), aimed at supporting the preclinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease (AD). The program focuses on funding activities such as medicinal chemistry, pharmacokinetics, and Investigational New Drug (IND)-enabling studies, with the goal of advancing viable therapies to address the significant public health challenge posed by AD. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and tribal organizations, with awards reaching up to $1.5 million over a period of up to five years for early-stage projects. Interested parties should submit their applications by November 5, 2027, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Safety and Efficacy of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Lewy Body Dementia and Amyloid-Beta Pathology (U01 - Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for clinical trials focused on the safety and efficacy of amyloid-beta directed antibody therapies in individuals with mild cognitive impairment and dementia associated with Lewy Body Dementia (LBD). This initiative aims to conduct Phase 2 placebo-controlled trials targeting mixed-etiology dementia populations, emphasizing the inclusion of diverse participants to ensure representative outcomes. The NIH plans to allocate up to $10 million for this project, which requires proposals to address relevant biomarkers and clinical diagnoses while incorporating community engagement strategies throughout the research process. Interested applicants can find more information and application details at the NIH grants website, with a submission deadline of January 24, 2025.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on Alzheimer's Disease (AD) and its related dementias (ADRD) through the R21 Clinical Trial Optional grant. This grant aims to support innovative research methods and tools that advance understanding and treatment of AD/ADRD, particularly focusing on interdisciplinary studies that require preliminary data for broader application in the field. Given the increasing prevalence of AD and the associated public health concerns, this funding opportunity is crucial for fostering new approaches to address the complexities of the disease and its impact on diverse populations. Interested applicants can apply for up to $275,000 over a two-year period, with the application deadline set for November 12, 2024. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-094.html.
    Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" funding opportunity, aimed at supporting innovative research projects that focus on the prevention, diagnosis, treatment, and care for individuals affected by these conditions. This initiative, part of the Small Business Technology Transfer Research (STTR) program, encourages the development of new therapies, devices, and healthcare programs, with an estimated $4 million allocated for approximately ten grants, including maximum budgets of $500,000 for Phase I and $2.5 million for Phase II awards. The funding opportunity underscores the federal commitment to addressing Alzheimer's research challenges through collaboration and innovation in the biomedical field. Interested applicants can find more information and application guidelines at the provided link, with the closing date for submissions set for September 5, 2025.
    Early and Late Stage Clinical Trials for the Spectrum of Alzheimers Disease/Alzheimers Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for early and late-stage clinical trials focused on Alzheimer's Disease (AD) and related dementias, as well as age-related cognitive decline. This initiative aims to develop and implement both pharmacological and non-pharmacological interventions to address cognitive and neuropsychiatric changes associated with these conditions, while also encouraging innovative trial designs and methodologies. Given the significant public health crisis posed by AD, which currently affects over six million Americans, this funding opportunity is part of a broader strategy to enhance research and develop effective therapies across the disease spectrum. Applications are due by January 7, 2025, and interested parties can find more information and submit proposals through the NIH ASSIST online system or contact NIH Grants Information at grantsinfo@nih.gov.
    Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), has announced a funding opportunity titled "Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)." This grant aims to support innovative research that elucidates the molecular mechanisms and functional implications of RNA modifications in relation to brain aging and Alzheimer's disease (AD) and related dementias (ADRD), including Lewy body dementia and frontotemporal dementia. The initiative is crucial for advancing understanding in this field, with the ultimate goal of identifying biomarkers and therapeutic targets that could lead to improved health outcomes for affected populations. Eligible applicants can request up to $500,000 in direct costs per year for projects lasting a maximum of five years, with a total funding allocation of $4 million for fiscal year 2025. Applications are due by November 1, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Pilot Studies for the Spectrum of Alzheimers Disease/Alzheimers Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting research grant applications for the "Pilot Studies for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline" initiative. This funding opportunity aims to collect pilot data to support early-stage testing of both pharmacological and non-pharmacological interventions targeting cognitive and neuropsychiatric changes associated with Alzheimer's Disease (AD) and related dementias (ADRD). The initiative is crucial in addressing the public health crisis posed by these conditions, emphasizing the need for effective therapies and improved trial designs. Interested applicants can apply for grants with an award ceiling of $325,000, with applications due by November 18, 2024. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-083.html.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)" grant, aimed at advancing research on Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity seeks to support high-priority research initiatives that address the growing public health crisis posed by these conditions, particularly among older adults. Eligible applicants include a diverse range of entities such as educational institutions, non-profits, and tribal governments, with funding decisions based on the scientific merit of proposals and the qualifications of the investigators. Applications are due by November 12, 2024, and interested parties can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional), aimed at supporting the pre-clinical and early-stage clinical development of innovative drug candidates for Alzheimer's disease. This funding opportunity focuses on projects that prevent, slow, or treat Alzheimer's disease, with an emphasis on compliance with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), while excluding basic disease mechanism studies. Eligible applicants include a diverse range of institutions and organizations, with funding available up to $1.5 million in direct costs over project periods of up to five years for early-stage and four years for late-stage projects. Interested parties should submit their applications by November 5, 2024, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD) (U01 - Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Optimization of Genome Editing Therapeutics for Alzheimer's Disease-Related Dementias (ADRD)" through a U01 cooperative agreement mechanism. This initiative aims to support the optimization of promising genome editing-based therapeutic leads for ADRD, focusing on preparing these candidates for Investigational New Drug (IND)-enabling studies. The funding is crucial for advancing research in various forms of ADRD, including Frontotemporal Dementia and Lewy Body Dementia, by refining therapeutic candidates to ensure their safety and efficacy. Interested applicants can apply for up to $1 million in funding, with a total budget commitment of up to $3 million per year for two awards, and must submit their applications by November 19, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.